Sotera Health Company (SHC)

In the past six months, Sotera Health Co. has experienced positive stock performance, with the stock price jumping 74.2%. In Q3 2025, Sotera Health reported adjusted EPS of $0.26, surpassing forecasts by 19.98%, and revenue reached $311 million, an increase of 9.1% year-over-year. In Q2 2025, Sotera Health reported revenue of $294.3 million, beating analyst estimates, and adjusted EPS of $0.20, also exceeding expectations. SHC shares have traded between a 52-week low of $9.53 and a 52-week high of $19.85, and as of February 7, 2026, the stock was trading at $17.75.

Specific detailed information on the demand seasonality for Sotera Health Co.'s products and services is not readily available. Management has highlighted "growing momentum across our core businesses," indicating increased customer demand in Q2 2025. Nordion's guidance is "heavily weighted toward the tail end", which could suggest some seasonality for the Cobalt-60 supply segment.

Sotera Health Co. is a global provider of sterilization solutions, lab testing, and advisory services for the healthcare industry. The company operates in the Healthcare sector, specifically in Healthcare Providers & Services and Laboratory Services. Sotera Health's business is structured into three segments: Sterigenics, which offers outsourced terminal sterilization and irradiation services; Nordion, a key provider of Cobalt-60; and Nelson Labs, which delivers outsourced microbiological and analytical chemistry testing and advisory services.

Sotera Health Company has a significant international presence, operating in the United States, Canada, Europe, and other regions. The company has operations spanning 48 facilities across 13 countries, with Nelson Labs having 12 global laboratory locations.

Sotera Health's brand reputation appears to be generally positive, built on its mission of "Safeguarding Global Health®" and its role as a critical partner in the healthcare supply chain. Customer satisfaction scores exceeded 80% in 2024. However, the company has faced significant litigation in the past related to ethylene oxide (EtO) emissions from its Sterigenics facilities, which negatively impacted its stock price and reputation.

Institutional investors hold a significant majority of Sotera Health Co. shares, with 87.66% held by institutional investors, 11.70% by individual investors, and 0.64% by insiders as of January 30, 2026. Major institutional owners include Warburg Pincus LLC, GTCR LLC, Darsana Capital Partners LP, Vanguard Group Inc., and BlackRock, Inc.